Clinical trial for people with hidradenitis suppurativa

Study 1030

We are looking for people with the skin condition hidradenitis suppurativa to participate in a clinical trial.

Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful lumps, abscesses, and scarring in skin folds such as the armpits, under the breasts, and in the groin.

The purpose of the study is to investigate the efficacy and safety of the investigational drug in people with moderate to severe hidradenitis suppurativa.

Target group: people with hidradenitis suppurativa, aged 18 and older

Criteria for participation:

• Have symptoms (lumps, boils, etc.) on at least two different parts of the body
• Have had symptoms for at least six months
• Previously treated with antibiotics without success and/or with side effects
• Do not have any other skin condition
• Be willing to use dual protection during heterosexual intercourse (i.e., condoms or male sterilization) AND use study-approved contraceptives, be sterilized, postmenopausal, and not be pregnant or breastfeeding (women)

The study consists of a screening period, a treatment period, and a follow-up period, spanning approximately 30 weeks. The treatment period lasts 16 weeks, during which you will receive a dose of the study drug or a placebo on four occasions. The study includes a total of 12 visits to our clinic in Uppsala.

The study is free of charge, and travel expenses may be reimbursed.

More information and registration

Would you like to participate in the study? Submit an expression of interest using the form below.

Do you have questions or want to know more? Call 018-30 33 99 or email info@ctc-ab.se.

The study has been approved by the Swedish Ethical Review Authority and the Swedish Medical Products Agency. Your participation is voluntary, and you may withdraw at any time. The information you provide will be processed in accordance with the General Data Protection Regulation (GDPR).

Register your interest